Business Description
Horizon Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : IE00BQPVQZ61
Description
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | 2.84 | |||||
| Interest Coverage | 8.26 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.06 | |||||
| Beneish M-Score | -2.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.5 | |||||
| 3-Year EBITDA Growth Rate | 42.2 | |||||
| 3-Year EPS without NRI Growth Rate | -8.5 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | 24.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.15 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.85 | |||||
| 9-Day RSI | 83.51 | |||||
| 14-Day RSI | 82.63 | |||||
| 6-1 Month Momentum % | -4.46 | |||||
| 12-1 Month Momentum % | 63.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.27 | |||||
| Quick Ratio | 4.09 | |||||
| Cash Ratio | 2.72 | |||||
| Days Inventory | 72.59 | |||||
| Days Sales Outstanding | 66.87 | |||||
| Days Payable | 29.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 0.04 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.21 | |||||
| Operating Margin % | 15.58 | |||||
| Net Margin % | 12.02 | |||||
| ROE % | 8.6 | |||||
| ROA % | 4.84 | |||||
| ROIC % | 9.37 | |||||
| ROC (Joel Greenblatt) % | 66.29 | |||||
| ROCE % | 6.27 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 61.76 | |||||
| Forward PE Ratio | 20.94 | |||||
| PE Ratio without NRI | 61.76 | |||||
| Price-to-Owner-Earnings | 39.46 | |||||
| PS Ratio | 7.42 | |||||
| PB Ratio | 4.98 | |||||
| Price-to-Tangible-Book | 26.31 | |||||
| Price-to-Free-Cash-Flow | 29.86 | |||||
| Price-to-Operating-Cash-Flow | 25.97 | |||||
| EV-to-EBIT | 51.77 | |||||
| EV-to-Forward-EBIT | 17.1 | |||||
| EV-to-EBITDA | 29.43 | |||||
| EV-to-Forward-EBITDA | 13.66 | |||||
| EV-to-Revenue | 7.28 | |||||
| EV-to-Forward-Revenue | 6.71 | |||||
| EV-to-FCF | 29.26 | |||||
| Price-to-Projected-FCF | 2.18 | |||||
| Price-to-Median-PS-Value | 1.48 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.47 | |||||
| Price-to-Graham-Number | 8.51 | |||||
| Earnings Yield (Greenblatt) % | 1.93 | |||||
| Forward Rate of Return (Yacktman) % | 22.35 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HZNP
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Horizon Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,644.406 | ||
| EPS (TTM) ($) | 1.87 | ||
| Beta | 0.79 | ||
| Volatility % | 63.24 | ||
| 14-Day RSI | 82.63 | ||
| 14-Day ATR ($) | 0.760957 | ||
| 20-Day SMA ($) | 113.4555 | ||
| 12-1 Month Momentum % | 63.61 | ||
| 52-Week Range ($) | 60.0303 - 115.71 | ||
| Shares Outstanding (Mil) | 228.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Horizon Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Horizon Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Horizon Therapeutics PLC Frequently Asked Questions
What is Horizon Therapeutics PLC(HZNP)'s stock price today?
The current price of HZNP is $115.50. The 52 week high of HZNP is $115.71 and 52 week low is $60.03.
When is next earnings date of Horizon Therapeutics PLC(HZNP)?
The next earnings date of Horizon Therapeutics PLC(HZNP) is 2023-11-02 Est..
Does Horizon Therapeutics PLC(HZNP) pay dividends? If so, how much?
Horizon Therapeutics PLC(HZNP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers